Episode 32: t(11;14) Multiple Myeloma and Role of Venetoclax with Dr. Rafael Fonseca and Dr. Martin Kaiser

Blood Cancer Talks

المحتوى المقدم من Rajshekhar Chakraborty and Ashwin Kishtagari, Rajshekhar Chakraborty, Ashwin Kishtagari, and Edward Cliff. يتم تحميل جميع محتويات البودكاست بما في ذلك الحلقات والرسومات وأوصاف البودكاست وتقديمها مباشرة بواسطة Rajshekhar Chakraborty and Ashwin Kishtagari, Rajshekhar Chakraborty, Ashwin Kishtagari, and Edward Cliff أو شريك منصة البودكاست الخاص بهم. إذا كنت تعتقد أن شخصًا ما يستخدم عملك المحمي بحقوق الطبع والنشر دون إذنك، فيمكنك اتباع العملية الموضحة هنا https://ar.player.fm/legal.

11M ago 58:50

MP3•منزل الحلقة

In this episode, we discuss the biology and management of t(11;14) multiple myeloma and the role of venetoclax with Dr. Rafael Fonseca and Dr. Martin Kaiser.

Here are the shownotes:

1. Excellent tweetorial thread by Dr. Fonseca highlighting some of the historical studies that identified t(11;14) and its prognostic impact in myeloma:

https://x.com/Rfonsi1/status/1206004966294294528?s=20

2. Natural history of t(11;14) myeloma in the era of PIs and IMiDs:

https://pubmed.ncbi.nlm.nih.gov/28655925/

3. BELLINI trial (Ven-Bort-Dex vs Bort-Dex in all-comers):

https://pubmed.ncbi.nlm.nih.gov/33129376/

4. Efficacy of Dara-VCD by cytogenetic subgroups in AL Amyloidosis:

https://pubmed.ncbi.nlm.nih.gov/36779691/

5. CANOVA Trial (Ven-Dex vs Pom-Dex in t[11;14]):

https://www.clinical-lymphoma-myeloma-leukemia.com/issue/S2152-2650(23)X0011-1?pageStart=0

6. Phase 1/2 trial on Daratumumab-Venetoclax-Dex in Relapsed/Refractory Myeloma:

https://pubmed.ncbi.nlm.nih.gov/34388020/

7. Phase 1/2 trial on Venetoclax-Carfilzomib-Dex in relapsed/refractory myeloma:

https://pubmed.ncbi.nlm.nih.gov/34470049/

51 حلقات

#Fitness #Medicine #Rajshekhar Chakraborty and Ashwin Kishtagari #Ashwin Kishtagari #Rajshekhar Chakraborty #Hematology #Cancer #Podcasting Education #Edward Cliff